Evidence map›Paper›PMID 32298288›Full record

Trial reportPloS one2020

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.

Ping-Ching Hsu, Susan A Kadlubar, Eric R Siegel, Lora J Rogers, Valentina K Todorova, L Joseph Su, Issam Makhoul

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00203502 (Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00203502 phase2completednot on this map

Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer

TypeinterventionalSponsorUniversity of ArkansasRan2005 to 2015Enrolled40ConditionsBreast CancerArmsBevacizumab, Cyclophosphamide, Docetaxel
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ping-Ching HsuDepartment of Environmental and Occupational Health, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.ORCID 0000-0002-1749-0662
Susan A KadlubarDepartment of Environmental and Occupational Health, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Eric R SiegelDepartment of Biostatistics, Colleges of Medicine and of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.ORCID 0000-0001-9824-6612
Lora J RogersDepartment of Epidemiology, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Valentina K TodorovaDepartment of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
L Joseph SuDepartment of Epidemiology, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Issam MakhoulDepartment of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.ORCID 0000-0001-8646-5658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

trial registrationClinicalTrials.gov Identifier: NCT00203502.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyPromoter Regions, GeneticAdultAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBromodomain Containing ProteinsCpG IslandsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3BDNA, NeoplasmFemaleHumansMiddle AgedNeoplasm ProteinsBevacizumabBRD9 protein, humanBromodomain Containing ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BDNA, NeoplasmNeoplasm ProteinsTranscription Factors

Identifiers

PMID32298288
PMCPMC7162481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.